AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action, Encourages Investors with Losses to Contact the Firm

Hagens Berman issued a shareholder-solicitation notice alerting Aardvark Therapeutics (AARD) investors to a pending securities fraud class action tied to its February 2025 IPO. The suit alleges the company failed to disclose cardiac safety findings (QRS prolongation) for ARD-101; the stock fell 56% after a February 2026 Phase 3 HERO trial pause and another 32.1% after an FDA clinical hold in May 2026. Lead plaintiff deadline is October 13, 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.